Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) has a beta value of 0.36 and has seen 2.45 million shares traded in the recent trading session. The company, currently valued at $24.72M, closed the last trade at $0.31 per share which meant it lost -$0.01 on the day or -2.82% during that session. The BCLI stock price is -483.87% off its 52-week high price of $1.81 and 58.06% above the 52-week low of $0.13. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.48 million shares traded. The 3-month trading volume is 559.21K shares.
The consensus among analysts is that Brainstorm Cell Therapeutics, Inc. (BCLI) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.03.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) trade information
Sporting -2.82% in the red today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the BCLI stock price touched $0.31 or saw a rise of 5.66%. Year-to-date, Brainstorm Cell Therapeutics, Inc. shares have moved 13.55%, while the 5-day performance has seen it change 12.77%. Over the past 30 days, the shares of Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) have changed -23.29%. Short interest in the company has seen 1.07 million shares shorted with days to cover at 2.38.
Brainstorm Cell Therapeutics, Inc. (BCLI) estimates and forecasts
Figures show that Brainstorm Cell Therapeutics, Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -7.46% over the past 6 months, with this year growth rate of 72.55%, compared to 17.50% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 10.57% over the past 5 years.
BCLI Dividends
Brainstorm Cell Therapeutics, Inc. is expected to release its next earnings report 2024-Aug-14 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI)’s Major holders
Insiders own 9.05% of the company shares, while shares held by institutions stand at 5.40% with a share float percentage of 5.93%. Investors are also buoyed by the number of investors in a company, with Brainstorm Cell Therapeutics, Inc. having a total of 52.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 1.4 million shares worth more than $0.79 million. As of 2024-03-31, VANGUARD GROUP INC held 2.1641% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 0.49 million shares as of 2024-03-31. The firm’s total holdings are worth over $0.28 million and represent 0.7558% of shares outstanding.
